Upadacitinib is expected to help AbbVie continue to lead in the immunology market after biosimilar competition emerges for adalimumab in 2023. The approval for the treatment of RA is one of 6 indications that AbbVie’s chief executive officer, Richard Gonzalez, said in a 2018 presentation that the company expects to have approved and launched by 2022.
Drug maker AbbVie has received approval for upadacitinib (Rinvoq), an orally administered Janus kinase (JAK) inhibitor for the treatment of patients with rheumatoid arthritis (RA) who have not responded adequately to methotrexate.
AbbVie expects the drug to become available to US patients later this month. The small-molecule drug, given at a dose of 15 mg once daily, will launch at a list price of $59,000 per patient per year, under the approximately $60,000 per patient per year for AbbVie’s flagship RA therapy, adalimumab (Humira). AbbVie said in a statement that its patient support program and copay card may bring out-of-pocket costs for eligible commercially-insured patients to $5 per month.
Upadacitinib is expected to help AbbVie continue to lead in the immunology market after biosimilar competition emerges for adalimumab in 2023. The approval for the treatment of RA is one of 6 indications that AbbVie’s chief executive officer, Richard Gonzalez, said in a 2018 presentation that the company expects to have approved and launched by 2022.
Upadacitinib was approved on the basis of data from the SELECT program, which enrolled approximately 4400 patients in 5 studies.
In one of those studies, the SELECT-COMPARE study, upadacitinib outperformed both placebo and AbbVie’s blockbuster brand-name adalimumab, Humira, in terms of the proportion of patients who achieved the American College of Rheumatology’s criteria for 20% improvement (ACR20) at week 12. The JAK inhibitor was also superior to adalimumab in terms of the proportion of patients who reached ACR50 at week 12, as well as in reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
The proportion of patients with adverse events (AEs) was higher for those given upadacitinib than those given placebo, but similar to those given adalimumab. Notably, thromboembolic events were similar across the 3 arms; 6 venous thromboembolic events occurred, 1 in the placebo arm, 2 in the upadacitinib arm, and 3 in the adalimumab arm. In a previous phase 3 study in the SELECT clinical program, SELECT-MONOTHERAPY, some concerns arose about the safety of the drug with respect to thromboembolic events.
In its label, upadacitinib carries a boxed warning that indicates that JAK inhibitors as a class have been liked with thrombosis; Pfizer’s tofacitinib (Xeljanz) was recently given a boxed warning on its label noting an increased risk for pulmonary embolism with a 10-mg twice-daily dose of the drug, which is currently approved for patients with ulcerative colitis. Baricitinib (Olumiant) also carries such a boxed warning, and was approved only at the lower of 2 proposed doses after the FDA’s Arthritis Advisory Committee voted against recommending approval of a higher dose given concerns about the potential for dose-dependent adverse events including thrombosis.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.